BRIEF published on 01/27/2025 at 22:20, 1 year 3 months ago Theralase's Interim Clinical Data to be Highlighted at 2025 AUA Annual Meeting Clinical Data Theralase Bladder Cancer Light-activated Therapy Urological Innovations
PRESS RELEASE published on 01/27/2025 at 22:15, 1 year 3 months ago Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting Theralase announces interim clinical data presentation at AUA Annual Meeting, showcasing promising results of light-activated Ruvidar™ in treating BCG-Unresponsive NMIBC CIS Theralase Bladder Cancer Interim Clinical Data Light-activated Ruvidar AUA Annual Meeting
BRIEF published on 12/09/2024 at 14:10, 1 year 5 months ago Theralase Expands Clinical Study Sites for Bladder Cancer Treatment in the U.S. Cancer Research Bladder Cancer Treatment Theralase Expansion Clinical Study Sites Ruvidar Activation
BRIEF published on 12/09/2024 at 14:10, 1 year 5 months ago Theralase élargit ses sites d'études cliniques pour le traitement du cancer de la vessie aux États-Unis Recherche Sur Le Cancer Expansion De La Théralase Traitement Du Cancer De La Vessie Sites D'études Cliniques Activation De Ruvidar
PRESS RELEASE published on 12/09/2024 at 14:05, 1 year 5 months ago Theralase(R) Launches Three New Clinical Study Sites in USA Theralase® launches new US Clinical Study Sites for bladder cancer treatment. Principal Investigators announced. Positive clinical data presented Clinical Data Theralase® Bladder Cancer US Clinical Study Sites
BRIEF published on 12/05/2024 at 13:05, 1 year 5 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
BRIEF published on 12/05/2024 at 13:05, 1 year 5 months ago Theralase Technologies étend son étude sur le cancer de la vessie au Canada Étude Clinique Cancer De La Vessie Ruvidar Technologies Théralase Expansion Au Canada
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 5 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 5 months ago Theralase publie son aperçu financier du troisième trimestre 2024 Placements Privés Dépenses De Recherche Et Développement Aperçu Financier De Theralase Chiffre D'affaires Et Marges Résultats De L'étude II
BRIEF published on 11/27/2024 at 23:10, 1 year 5 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
Published on 05/16/2026 at 01:15, 15 hours 48 minutes ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 17 hours 3 minutes ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 17 hours 53 minutes ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/15/2026 at 23:00, 18 hours 3 minutes ago Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency
Published on 05/16/2026 at 16:08, 55 minutes ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 20 hours 53 minutes ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 22 hours 53 minutes ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 15:08, 1 day 1 hour ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 1 day 2 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 1 day 6 hours ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 2 days 8 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 2 days 23 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
